Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe Oct 18, 2019 7:30am EDT
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia Sep 23, 2019 7:30am EDT
Rigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference Aug 28, 2019 7:30am EDT
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update Aug 06, 2019 4:01pm EDT
Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results Jul 30, 2019 7:30am EDT
Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA) Jun 13, 2019 7:30am EDT
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia May 16, 2019 7:30am EDT
